Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Elevance Health, Inc. (NYSE:ELV)

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased between $1,001 and $15,000 in Elevance Health (NYSE: ELV) stock on August 5th, as disclosed in a filing on September 12th.
• Elevance Health's stock has shown a recent 0.9% increase, currently trading at $309.78, with a market capitalization of $69.76 billion.
• The company announced a quarterly dividend of $1.71, with a yield of 2.2%, payable on September 25th to investors of record by September 10th.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Elevance Health, Inc. (NYSE:ELV). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Elevance Health stock on August 5th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Chart Industries NYSE: GTLS on 9/2/2025.
• Purchased $1,001 - $15,000 in shares of Avient NYSE: AVNT on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Intapp NASDAQ: INTA on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 8/26/2025.
• Sold $1,001 - $15,000 in shares of Fortive NYSE: FTV on 8/26/2025.

Elevance Health Trading Down 0.6%

Shares of ELV traded down $1.87 during mid-day trading on Friday, reaching $313.90. 3,015,351 shares of the company's stock traded hands, compared to its average volume of 1,942,901. The stock has a market cap of $70.68 billion, a P/E ratio of 13.36, a P/E/G ratio of 1.15 and a beta of 0.59. The stock's 50-day moving average is $303.03 and its two-hundred day moving average is $367.63. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $542.22. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Thursday, July 17th. The company reported $8.84 EPS for the quarter, missing analysts' consensus estimates of $9.30 by ($0.46). Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The business had revenue of $49.42 billion for the quarter, compared to the consensus estimate of $48.26 billion. During the same period in the prior year, the company posted $10.12 EPS. The company's quarterly revenue was up 14.3% compared to the same quarter last year. Research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 25th. Stockholders of record on Wednesday, September 10th will be paid a dividend of $1.71 per share. The ex-dividend date of this dividend is Wednesday, September 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 2.2%. Elevance Health's dividend payout ratio is currently 29.11%.

Insider Activity

In related news, Director Susan D. Devore purchased 1,200 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average cost of $312.15 per share, with a total value of $374,580.00. Following the purchase, the director owned 3,502 shares of the company's stock, valued at $1,093,149.30. This represents a 52.13% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Gail Boudreaux purchased 8,500 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was bought at an average cost of $286.94 per share, for a total transaction of $2,438,990.00. Following the completion of the purchase, the chief executive officer directly owned 151,020 shares in the company, valued at $43,333,678.80. This represents a 5.96% increase in their position. The disclosure for this purchase can be found here. 0.29% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Elevance Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Elevance Health by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company's stock worth $8,890,419,000 after purchasing an additional 704,790 shares during the period. Sanders Capital LLC grew its position in Elevance Health by 24.7% during the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company's stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership grew its position in Elevance Health by 9.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company's stock worth $1,429,498,000 after purchasing an additional 324,399 shares during the period. Norges Bank acquired a new stake in Elevance Health during the 2nd quarter worth about $1,148,379,000. Finally, Orbis Allan Gray Ltd grew its position in Elevance Health by 31.4% during the 1st quarter. Orbis Allan Gray Ltd now owns 2,849,173 shares of the company's stock worth $1,239,276,000 after purchasing an additional 680,228 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Elevance Health from $472.00 to $384.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 22nd. Wall Street Zen cut Elevance Health from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Guggenheim dropped their price objective on Elevance Health from $447.00 to $360.00 and set a "buy" rating on the stock in a research note on Friday, July 18th. Leerink Partners restated a "market perform" rating and set a $310.00 target price (down previously from $510.00) on shares of Elevance Health in a report on Friday, July 18th. Finally, Morgan Stanley decreased their price objective on Elevance Health from $428.00 to $316.00 and set an "overweight" rating for the company in a report on Friday, July 18th. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $411.06.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.